To address these challenges, optimizations for GPNMB-targeted therapies can be tailored to mitigate such harms—for instance, using moderate-affinity antibodies to ensure binding only to tumor tissues with high GPNMB expression, and designing administration regimens that first neutralize shed ECD in the bloodstream before delivering therapeutic agents. The gene discussed is GPNMB; the disease is neoplasm.